Primary Objective:
To evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo as measured by:
Incidence of Adverse Events [ Time Frame: 52 ...
This study focuses on individuals with ulcerative colitis (UC) that has been assessed as being moderate to severe. The purpose of the study is to determine whether ...
Primary Objective:
Assess overall sensitivity and specificity of Oncoguard Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Secondary Objective(s):
Assess performance of Oncoguard Liver in confirmed HCC and non-HCC population.
Assess ...
Primary:
To investigate the effect of treatment with oral linerixibat compared with placebo on itch in PBC patients with cholestatic pruritus over 24 weeks (Part A)
Secondary:
- To evaluate the early effects ...
Co-Primary Effectiveness Endpoint 1:
Responder Rate (RR) dichotomized at 5% TBWL at 48 weeks is significantly greater than 50%.
Co-Primary Effectiveness Endpoint 2:
Treatment Group mean %TBWL is significantly greater than Control Group ...
